Literature DB >> 11258978

Development and application of a sensitive and rapid immunoassay for the quantitation of N7-methyldeoxyguanosine in DNA samples.

K L Harrison1, M Wood, N P Lees, C N Hall, G P Margison, A C Povey.   

Abstract

N7-Methyldeoxyguanosine (N7-MedG) in DNA is a biomarker of exposure to environmental and endogenous methylating agents and may be of use in epidemiological studies. To quantitate N7-MedG in human samples, a sensitive assay system that uses only small quantities of DNA (<10 microg) is required. To this end, polyclonal antibodies against the imidazole ring-opened form of N7-MedG have been used to develop a highly sensitive immunoslot blot (ISB) assay. The limit of detection of the assay is 0.10 micromol of N7-MedG/mol of deoxyguanosine (dG) using 1 microg of DNA per analysis. The method was optimized using in vitro-methylated calf thymus DNA and then applied to a study of DNA methylation in liver and brain tissues of mice following a single iv dose of the antitumor agent Temozolomide. The amount of N7-MedG in both tissues was strictly proportional to dose over a range of 10-200 mg of Temozolomide/kg of body weight. The ISB assay was then validated using pyloric DNA of rats treated with N-methyl-N'-nitro-N-nitrosoguanidine and DNA samples from human bladder tumors, for both of which N7-MedG levels had already been quantitated by an HPLC/(32)P-postlabeling method previously described. The results showed a high degree of correlation (r = 0.98) between the two assays. The ISB assay was then applied to a range of human samples. A series of peripheral blood mononuclear cell DNA samples from cancer patients following treatment with Temozolomide had levels of N7-MedG ranging from 0.22 to 320 micromol/mol of dG. DNA samples from colon carcinoma and normal colorectal mucosa from individuals not known to be exposed to methylating agents contained levels of 0.11-1.34 micromol of N7-MedG/mol of dG. The ISB assay offers the potential for the rapid and high-throughput analysis of DNA obtained from routine biopsies and blood samples, thus enabling the determination of the extent of human exposure to environmental and endogenous sources of methylating agents in large-scale biomonitoring studies.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11258978     DOI: 10.1021/tx000071b

Source DB:  PubMed          Journal:  Chem Res Toxicol        ISSN: 0893-228X            Impact factor:   3.739


  9 in total

1.  Human colorectal mucosal O6-alkylguanine DNA-alkyltransferase activity and DNA-N7-methylguanine levels in colorectal adenoma cases and matched referents.

Authors:  N P Lees; K L Harrison; C N Hall; G P Margison; A C Povey
Journal:  Gut       Date:  2006-08-04       Impact factor: 23.059

2.  Simultaneous determination of N7-alkylguanines in DNA by isotope-dilution LC-tandem MS coupled with automated solid-phase extraction and its application to a small fish model.

Authors:  Mu-Rong Chao; Chien-Jen Wang; Cheng-Chieh Yen; Hsi-Hsien Yang; Yao-Cheng Lu; Louis W Chang; Chiung-Wen Hu
Journal:  Biochem J       Date:  2007-03-15       Impact factor: 3.857

3.  Epigenetic-genetic interactions in the APC/WNT, RAS/RAF, and P53 pathways in colorectal carcinoma.

Authors:  Yutaka Suehiro; Chi Wai Wong; Lucian R Chirieac; Yutaka Kondo; Lanlan Shen; C Renee Webb; Yee Wai Chan; Annie S Y Chan; Tsun Leung Chan; Tsung-Teh Wu; Asif Rashid; Yuichiro Hamanaka; Yuji Hinoda; Rhonda L Shannon; Xuemei Wang; Jeffrey Morris; Jean-Pierre J Issa; Siu Tsan Yuen; Suet Yi Leung; Stanley R Hamilton
Journal:  Clin Cancer Res       Date:  2008-05-01       Impact factor: 12.531

Review 4.  Mechanistic Evidence for Red Meat and Processed Meat Intake and Cancer Risk: A Follow-up on the International Agency for Research on Cancer Evaluation of 2015.

Authors:  Robert J Turesky
Journal:  Chimia (Aarau)       Date:  2018-10-31       Impact factor: 1.509

Review 5.  The formation and biological significance of N7-guanine adducts.

Authors:  Gunnar Boysen; Brian F Pachkowski; Jun Nakamura; James A Swenberg
Journal:  Mutat Res       Date:  2009-05-22       Impact factor: 2.433

6.  A phase I study of the safety and tolerability of olaparib (AZD2281, KU0059436) and dacarbazine in patients with advanced solid tumours.

Authors:  O A Khan; M Gore; P Lorigan; J Stone; A Greystoke; W Burke; J Carmichael; A J Watson; G McGown; M Thorncroft; G P Margison; R Califano; J Larkin; S Wellman; M R Middleton
Journal:  Br J Cancer       Date:  2011-02-15       Impact factor: 7.640

7.  The marker of alkyl DNA base damage, N7-methylguanine, is associated with semen quality in men.

Authors:  B Altakroni; C Nevin; M Carroll; C Murgatroyd; G Horne; D R Brison; A C Povey
Journal:  Sci Rep       Date:  2021-02-04       Impact factor: 4.379

8.  O(6)-methylguanine-DNA methyltransferase depletion and DNA damage in patients with melanoma treated with temozolomide alone or with lomeguatrib.

Authors:  A J Watson; M R Middleton; G McGown; M Thorncroft; M Ranson; P Hersey; G McArthur; I D Davis; D Thomson; J Beith; A Haydon; R Kefford; P Lorigan; P Mortimer; A Sabharwal; O Hayward; G P Margison
Journal:  Br J Cancer       Date:  2009-04-21       Impact factor: 7.640

9.  IGF-1R inhibition induces schedule-dependent sensitization of human melanoma to temozolomide.

Authors:  Roger Ramcharan; Tamara Aleksic; Wilfride Petnga Kamdoum; Shan Gao; Sophia X Pfister; Jordan Tanner; Esther Bridges; Ruth Asher; Amanda J Watson; Geoffrey P Margison; Mick Woodcock; Emmanouela Repapi; Ji-Liang Li; Mark R Middleton; Valentine M Macaulay
Journal:  Oncotarget       Date:  2015-11-24
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.